European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis
J.P. Thyssen
(1, 2)
,
C. Vestergaard
(3)
,
M. Deleuran
(3)
,
M.S. Bruin‐weller
(4)
,
T. Bieber
(5)
,
A. Taieb
(6)
,
J. Seneschal
(6)
,
M.J. Cork
(7)
,
C. Paul
(8)
,
C. Flohr
(9)
,
S. Weidinger
(10)
,
M. Trzeciak
(11)
,
T. Werfel
(11)
,
A. Heratizadeh
(12)
,
Sebastien Barbarot
(13, 12)
,
U. Darsow
(14)
,
D. Simon
(15)
,
A. Torrelo
(16)
,
P.V. Chernyshov
(17)
,
J.‐f. Stalder
(18)
,
C. Gelmetti
(19)
,
Z. Szalai
(20)
,
Å. Svensson
(21)
,
L.B. Kobyletzki
(21)
,
L. de Raeve
(22)
,
R. Fölster‐holst
(23)
,
S. Cristen‐zaech
(24)
,
D. Hijnen
(25)
,
U. Gieler
(13)
,
J. Ring
(26)
,
A. Wollenberg
(27)
1
Herlev and Gentofte Hospital
2 CORGIS - Copenhagen Research Group for Inflammatory Skin
3 Aarhus University Hospital
4 Univ Med Ctr Utrecht, Dept Pediat Gastroenterol
5 University Hospital Bonn
6 UB - Université de Bordeaux
7 University of Sheffield [Sheffield]
8 UT3 - Université Toulouse III - Paul Sabatier
9 King‘s College London
10 Schleswig-Holstein University Hospitals
11 MHH - Medizinische Hochschule Hannover = Hannover Medical School
12 PhAN - Physiopathologie des Adaptations Nutritionnelles
13 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
14 Inselspital - Bern University Hospital [Berne]
15 HIUNJ - Hospital Infantil Universitario Niño Jesús
16 National Medical University
17 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
18 UNIMI - Università degli Studi di Milano = University of Milan
19 Heim Pál Children's Hospital
20 Skane University Hospital [Malmo]
21 Skane University Hospital [Lund]
22 University Clinic Schleswig–Holstein
23 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
24 Centre médical Érasme
25 JLU - Justus-Liebig-Universität Gießen = Justus Liebig University
26 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
27 Klinikum der Universität [München]
2 CORGIS - Copenhagen Research Group for Inflammatory Skin
3 Aarhus University Hospital
4 Univ Med Ctr Utrecht, Dept Pediat Gastroenterol
5 University Hospital Bonn
6 UB - Université de Bordeaux
7 University of Sheffield [Sheffield]
8 UT3 - Université Toulouse III - Paul Sabatier
9 King‘s College London
10 Schleswig-Holstein University Hospitals
11 MHH - Medizinische Hochschule Hannover = Hannover Medical School
12 PhAN - Physiopathologie des Adaptations Nutritionnelles
13 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
14 Inselspital - Bern University Hospital [Berne]
15 HIUNJ - Hospital Infantil Universitario Niño Jesús
16 National Medical University
17 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
18 UNIMI - Università degli Studi di Milano = University of Milan
19 Heim Pál Children's Hospital
20 Skane University Hospital [Malmo]
21 Skane University Hospital [Lund]
22 University Clinic Schleswig–Holstein
23 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
24 Centre médical Érasme
25 JLU - Justus-Liebig-Universität Gießen = Justus Liebig University
26 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
27 Klinikum der Universität [München]
J.P. Thyssen
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1109695
Connectez-vous pour contacter l'auteur
M. Deleuran
- Fonction : Auteur
- PersonId : 800822
- ORCID : 0000-0003-0593-9925
J. Seneschal
- Fonction : Auteur
- PersonId : 775154
- ORCID : 0000-0003-1139-0908
- IdRef : 129977373
C. Paul
- Fonction : Auteur
- PersonId : 832981
- ORCID : 0000-0003-0165-5263
- IdRef : 093327749
A. Wollenberg
- Fonction : Auteur
- PersonId : 800778
- ORCID : 0000-0003-0177-8722
Résumé
Background: Surgery is a radical treatment for hidradenitis suppurativa (HS) and may be considered as the only one potentially curative. Objectives: To characterize HS recurrence in patients after surgery and assess the risk factors of recurrence. Methods: We conducted a monocentric retrospective cohort study. All consecutive patients who had surgery (January 1, 2012 to March 31, 2017) were included. We estimated the rate of recurrence of HS lesions after surgery (<1 cm from the scar), and recurrence-associated factors were analysed by univariate then multivariate logistic regression, estimating odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 75 patients [median age 31.4 years (range 16–71); 36 females], corresponding to 115 interventions were included. The Hurley score at surgery was III for 70 (60%) patients. In total, 61/115 (53%) interventions involved wide excision and 50 (43%) limited local excision. The localizations were axillary folds (n = 46; 40%), buttocks (n = 15, 13%), genital area (n = 13; 11%), perineal area (n = 12; 10%) and inguinal folds (n = 18; 16%). We observed 11 (10%) complications and 40 (35%) recurrences. On multivariate analysis, probability of recurrence was associated with only one-stage surgical closure [OR 3.2 (95% CI 1.4–7.3), P = 0.005]. Overall, 44 (52%) patients were completely satisfied and 22 (26%) partially satisfied, and most (81%) considered the surgery the best treatment. Conclusions: Hidradenitis suppurativa recurrence in our study was 35% and associated with one-stage surgical closures, but two-thirds of patients were satisfied with surgical treatment and would recommend surgery.